19 November 2017
News and Views
Links and Services
A study in the latest issue of the Alimentary Pharmacology & Therapeutics predicts Crohn’s disease relapse with fecal calprotectin in infliximab responders.
Fecal calprotectin is a reliable tool for predicting Crohn’s disease relapse in patients with sus
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors